newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

  • IGC Pharma expanded its AI-powered in-Silico drug discovery platform to accelerate therapeutic candidate identification & optimization for Alzheimer's disease.
  • New integrated methodologies include retrosynthetic analysis, molecular docking, toxicology, genotoxic assessments, & predictive bioactivity modeling.
  • These enhancements aim to reduce time & resources for compound screening & lead optimization while prioritizing promising candidates via computational simulation.
  • The platform now predicts toxicity risks to reduce animal testing & forecasts biological activity across targets including CB1, CB2, dopamine, serotonin, muscarinic, GLP-1, & GIP receptors.
  • Molecular docking simulations assess binding affinity & orientation, while retrosynthetic analysis facilitates the design of feasible synthetic pathways for complex molecules.
  • Lead candidate IGC-AD1 is currently in Phase 2 clinical trials for Alzheimer's agitation & shows potential to inhibit amyloid-beta aggregation & enhance mitochondrial function.
  • The TGR-63 program focuses on amyloid plaque reduction with preclinical data showing significant clearance in the cortex & hippocampus.
  • Additional pipeline assets include IGC-1C, a dual-action candidate targeting tau proteins & GLP-1 receptors, & IGC-1A, an AI-identified GLP-1 receptor agonist for metabolic & neurological disorders.
  • IGC Pharma holds over 30 patent filings with 12 patents granted & utilizes its AI-driven MINT-AD model to transform neurodegenerative disease treatment development.